Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes

Vaccine

Volumn 21, Issue 23, 2003, Pages 3319-3329

  Li, Wai Ming ^a,b   Dragowska, Wieslawa H ^b   Bally, Marcel B ^a,b,c   Schutze Redelmeier, Marie Paule ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c Celator Technologies Inc   (Canada)

Author keywords

CpG oligodeoxynucleotide; CTL epitope; Liposomes

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; IMMUNOLIPOSOME; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; PEPTIDE; SODIUM CHLORIDE;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; SPLEEN CELL; T LYMPHOCYTE; VACCINATION;

EID: 0037529140     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00172-5     Document Type: Article

References (49)

1. Krieg A.M., Yi A.K., Hartmann G. Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol. Ther. 84:1999;113-120.
2. Wagner H., Hacker H., Lipford G.B. Immunostimulatory DNA sequences help to eradicate intracellular pathogens. Springer Semin. Immunopathol. 22:2000;147-152.
3. Klinman D.M., Kamstrup S., Verthelyi D., Gursel I., Ishii K.J., Takeshita F.et al. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin. Immunopathol. 22:2000;173-183.
4. Weiner G.J. Immunostimulatory DNA sequences and cancer therapy. Springer Semin. Immunopathol. 22:2000;107-116.
5. McCluskie M.J., Weeratna R.D., Davis H.L. The role of CpG in DNA vaccines. Springer Semin. Immunopathol. 22:2000;125-132.
6. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
7. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15553-15558.
8. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:1997;2340-2344.
9. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M.et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876. [published erratum appears in J Immunol 1 March 1999;162(5):3103].
10. Davila E., Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol. 165:2000;539-547. [in process citation].
11. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J.et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106:2000;124-134.
12. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S.et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18:2000;509-514.
13. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 164:2000;5575-5582.
14. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J.et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30:2000;1939-1947.
15. Gursel I., Gursel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of cpg oligonucleotides. J. Immunol. 167:2001;3324-3328.
16. Li W.M., Bally M.B., Schutze-Redelmeier M.P. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine. 20:2001;148-157.
17. Disis ML, Cheever MA. In: Vande WGF, George K, editors. Advances in cancer research. Toronto: Academic Press; 1997. p. 343-71.
18. Ross J.S., Fletcher J.A. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 112:1999;S53-S67.
19. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L.et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:1999;2639-2648.
20. Nagata Y., Furugen R., Hiasa A., Ikeda H., Ohta N., Furukawa K.et al. Peptides derived from a wild-type murine proto-oncogene c-erbB- 2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159:1997;1336-1343.
21. Sun S., Kishimoto H., Sprent J. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T-cell responses to specific antigen. J. Exp. Med. 187:1998;1145-1150.
22. Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta. 858:1986;161-168.
23. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:1959;911-937.
24. Ignatius R., Mahnke K., Rivera M., Hong K., Isdell F., Steinman R.M.et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood. 96:2000;3505-3513.
25. Shirota H., Sano K., Hirasawa N., Terui T., Ohuchi K., Hattori T.et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J. Immunol. 167:2001;66-74.
26. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S.et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 98:2001;9237-9242.
27. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U.S.A. 94:1997;10833-10837.
28. Vabulas R.M., Pircher H., Lipford G.B., Hacker H., Wagner H. CpG-DNA activates in vivo T-cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T-cell responses. J. Immunol. 164:2000;2372-2378.
29. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 96:1999;9305-9310.
30. Hacker H., Mischak H., Miethke T., Liptay S., Schmid R., Sparwasser T.et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17:1998;6230-6240.
31. Vogel J.C., Udey M.C. Activation of skin dendritic cells by immunostimulatory DNA. Springer Semin. Immunopathol. 22:2000;45-54.
32. Stacey K.J., Sester D.P., Sweet M.J., Hume D.A. Macrophage activation by immunostimulatory DNA. Curr. Top. Microbiol. Immunol. 247:2000;41-58.
33. Cho H.J., Hayashi T., Datta S.K., Takabayashi K., Van Uden J.H., Horner A.et al. IFN-alphabeta promote priming of antigen-specific CD8(+) and CD4(+) T lymphocytes by immunostimulatory DNA-based vaccines. J. Immunol. 168:2002;4907-4913.
34. Nouri-Shirazi M., Banchereau J., Fay J., Palucka K. Dendritic cell based tumor vaccines. Immunol. Lett. 74:2000;5-10.
35. Weijzen S., Meredith S.C., Velders M.P., Elmishad A.G., Schreiber H., Kast W.M. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J. Immunol. 166:2001;7151-7157.
36. Ludewig B., Barchiesi F., Pericin M., Zinkernagel R.M., Hengartner H., Schwendener R.A. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine. 19:2000;23-32.
37. Lipford G.B., Wagner H., Heeg K. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. Vaccine. 12:1994;73-80.
38. Chikh G.G., Schutze-Redelmeier M.P. Liposomal delivery of CTL epitopes to dendritic cells. Biosci. Rep. 22:2002;339-353.
39. Chikh G.G., Kong S., Bally M.B., Meunier J.C., Schutze-Redelmeier M.P. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J. Immunol. 167:2001;6462-6470.
40. Miller M.D., Gould-Fogerite S., Shen L., Woods R.M., Koenig S., Mannino R.J.et al. Vaccination of Rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. J. Exp. Med. 176:1992;1739-1744.
41. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R.et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
42. Yi A.K., Tuetken R., Redford T., Waldschmidt M., Kirsch J., Krieg A.M. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160:1998;4755-4761.
43. Yi A.K., Hornbeck P., Lafrenz D.E., Krieg A.M. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J. Immunol. 157:1996;4918-4925.
44. Krieg A.M. Signal transduction induced by immunostimulatory CpG DNA. Springer Semin. Immunopathol. 22:2000;97-105.
45. Zhou F., Rouse B.T., Huang L. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J. Immunol. 149:1992;1599-1604.
46. Wijburg O.L., van den Dobbelsteen G.P., Vadolas J., Sanders A., Strugnell R.A., van Rooijen N. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur. J. Immunol. 28:1998;479-487.
47. Nair S., Buiting A.M., Rouse R.J., Van Rooijen N., Huang L., Rouse B.T. Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. Int. Immunol. 7:1995;679-688.
48. Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5:1999;1289-1297.
49. Knutson K.L., Schiffman K., Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107:2001;477-484.